Table 2.
Characteristics at Baseline (N=45 151)
| Demographic Characteristic | Statin‐Maintained (N=33 623) | Statin‐Reduced (N=3175) | Statin‐Discontinued (N=8353) | P Value |
|---|---|---|---|---|
| Men, n (%) | 19 084 (56.8) | 1849 (58.2) | 4688 (56.1) | 0.12 |
| Age, y, mean±SD | 65.1±11.7 | 64.9±11.6 | 65.6±11.8 | 0.001 |
| <65 | 15 771 (46.9) | 1515 (47.7) | 3721 (44.6) | 0.0005 |
| 65 to 74 | 10 016 (29.8) | 937 (29.5) | 2535 (30.4) | |
| ≥75 | 7836 (23.3) | 723 (22.8) | 2097 (25.1) | |
| Comorbidity, n (%) | ||||
| Hypertension | 28 287 (84.1) | 2650 (83.5) | 7066 (84.6) | 0.31 |
| Diabetes mellitus | 16 815 (50.0) | 1589 (50.1) | 4145 (49.6) | 0.81 |
| Ischemic heart disease | 10 075 (30.0) | 913 (28.8) | 2649 (31.7) | 0.001 |
| Stroke history before index stroke | 5655 (16.8) | 456 (14.4) | 1478 (17.7) | 0.0001 |
| Chronic kidney disease | 1359 (4.0) | 127 (4.0) | 360 (4.3) | 0.52 |
| Heart failure | 2671 (7.9) | 217 (6.8) | 723 (8.7) | 0.004 |
| Chronic obstructive pulmonary disease | 4996 (14.9) | 446 (14.1) | 1315 (15.7) | 0.04 |
| Peripheral vascular disease | 734 (2.2) | 58 (1.8) | 205 (2.5) | 0.10 |
| Sleep apnea | 143 (0.4) | 14 (0.4) | 33 (0.4) | 0.91 |
| Antihypertensive therapya | ||||
| On days 91 to 180 | 22 640 (67.3) | 2146 (67.6) | 5705 (68.3) | 0.24 |
| Stroke severity index | 0.0008 | |||
| Mild | 26 718 (79.5) | 2545 (80.2) | 6523 (78.1) | |
| Moderate | 4503 (13.4) | 450 (14.2) | 1201 (14.4) | |
| Severe | 2402 (7.1) | 180 (5.7) | 629 (7.5) | |
| Complications on days 91 to 180, n (%) | ||||
| Elevated transaminases | 7 (0.02) | 2 (0.06) | 1 (0.01) | 0.25b |
| Abnormal serum enzyme | 2 (0.01) | 0 (0.00) | 1 (0.01) | 0.75b |
| Rhabdomyolysis | 0 | 0 | 0 | ··· |
| Myalgia and myositis | 1828 (5.4) | 167 (5.3) | 471 (5.6) | 0.67 |
| Cognitive impairment | 65 (0.2) | 1 (0.03) | 15 (0.2) | 0.12 |
a
Antihypertensive therapy: angiotensin‐converting enzyme inhibitor, angiotensin II receptor blockers, calcium channel blockers, and diuretics.
b
More than 25% of the cells have expected counts less than 5. Chi‐squared may not be a valid test.